General Information of Drug (ID: DMZ2YBE)

Drug Name
Lexipafant Drug Info
Synonyms
LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
Indication
Disease Entry ICD 11 Status REF
Nerve injury ND56.4 Phase 2 [1]
Hepatovirus infection 1E51 Investigative [2]
Cross-matching ID
PubChem CID
9804204
CAS Number
CAS 139133-26-9
TTD Drug ID
DMZ2YBE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [2]
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Platelet-activating factor receptor (PTAFR) DTT PTAFR 6.345 5.947 6.084 6.253
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Nerve injury
ICD Disease Classification ND56.4
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet-activating factor receptor (PTAFR) DTT PTAFR 3.53E-02 0.33 2.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.
2 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
3 Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.